Is there a rationale for heparin use among severe COVID-19 patients?

Savioli, Felicio.
Einstein (Säo Paulo) ; 18: eED5758, 2020.
Artículo en Inglés | LILACS | ID: biblio-1133777

Documentos relacionados

  1. Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties.
  2. Is there a rationale for heparin use among severe COVID-19 patients?
  3. Pretreatment with a dual antiplatelet and anticoagulant (APAC) reduces ischemia-reperfusion injury in a mouse model of temporary middle cerebral artery occlusion-implications for neurovascular procedures.
  4. Why anticoagulant studies on sepsis fail frequently --- start with SCARLET.
  5. UMI-77 Modulates the Complement Cascade Pathway and Inhibits Inflammatory Factor Storm in Sepsis Based on TMT Proteomics and Inflammation Array Glass Chip.
  6. Reactive Oxygen Species in Venous Thrombosis.
  7. Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia.
  8. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential.
  9. Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis.
  10. Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds.